

## Trevi Therapeutics to Participate in Upcoming June Conferences

May 29, 2025

NEW HAVEN, Conn., May 29, 2025 /PRNewswire/ -- [Trevi Therapeutics, Inc.](#) (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in June.

### **American Cough Conference**

June 6 – 7, 2025, Dulles, Virginia

**Oral Presentation:** June 6, 4:05 p.m. ET

**Presentation:** Baseline demographics and characteristics from the RIVER trial evaluating nalbuphine extended-release tablets in patients with refractory chronic cough

**Trevi Representatives:** Jennifer Good, President and CEO, James Cassella, Ph.D., CDO, Danine Summers, VP of Medical Affairs and Abbey Nakano, Pharm.D., AD of Medical Affairs

[Register here](#)

### **CPDD 87<sup>th</sup> Annual Scientific Meeting**

June 14 – 18, 2025, New Orleans, Louisiana

**Poster Presentation:** June 18, 2:00 p.m. CT

**Poster:** Assessment of Human Abuse Potential of Nalbuphine in Non-Dependent Recreational Drug Users

**Poster Session:** 4

**Trevi Representative:** Thomas Sciascia, M.D., Co-Founder and CSO

[Register here](#)

### **BIO International Convention**

June 16 – 19, 2025, Boston, Massachusetts

**Corporate Presentation:** June 17, 12:15 p.m. ET

**Trevi Representatives:** Jennifer Good, President and CEO, and Farrell Simon, Pharm.D., CCO

[Register here](#)

### **About Trevi Therapeutics, Inc.**

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically significant reduction in cough frequency in clinical trials with IPF chronic cough patients and RCC patients. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.

Chronic cough is a highly prevalent condition in IPF patients, impacting up to 85% of the IPF population. There are ~150,000 U.S. IPF patients and the impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough and any associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients.

Refractory chronic cough has no approved therapies in the U.S. and is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, and upper airway cough syndrome or post-nasal drip) and includes unexplained chronic cough. RCC affects ~2-3 million patients in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is a highly debilitating disease and accompanied by a wide range of complications, ranging from urinary incontinence in females to sleep disruption and social embarrassment that causes significant social and economic burdens for patients and those around them.

Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.

For more information, visit [www.TreviTherapeutics.com](http://www.TreviTherapeutics.com) and follow Trevi on [X](#) (formerly Twitter) and [LinkedIn](#).

### **Investor Contact**

Jonathan Carlson

Trevi Therapeutics, Inc.

(203) 654 3286

[carlsonj@trevitherapeutics.com](mailto:carlsonj@trevitherapeutics.com)

**Media Contact**

Rosalia Scampoli

914-815-1465

[rscampoli@marketcompr.com](mailto:rscampoli@marketcompr.com)

SOURCE Trevi Therapeutics, Inc.